JP2025186248A5 - - Google Patents
Info
- Publication number
- JP2025186248A5 JP2025186248A5 JP2025135655A JP2025135655A JP2025186248A5 JP 2025186248 A5 JP2025186248 A5 JP 2025186248A5 JP 2025135655 A JP2025135655 A JP 2025135655A JP 2025135655 A JP2025135655 A JP 2025135655A JP 2025186248 A5 JP2025186248 A5 JP 2025186248A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cenk
- composition
- composition according
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156269P | 2021-03-03 | 2021-03-03 | |
| US63/156,269 | 2021-03-03 | ||
| US202163217097P | 2021-06-30 | 2021-06-30 | |
| US63/217,097 | 2021-06-30 | ||
| PCT/US2022/018290 WO2022187207A1 (en) | 2021-03-03 | 2022-03-01 | Highly potent m-cenk cells and methods |
| JP2023553498A JP7792426B2 (ja) | 2021-03-03 | 2022-03-01 | 極めて強力なｍ－ｃｅｎｋ細胞及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553498A Division JP7792426B2 (ja) | 2021-03-03 | 2022-03-01 | 極めて強力なｍ－ｃｅｎｋ細胞及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025186248A JP2025186248A (ja) | 2025-12-23 |
| JP2025186248A5 true JP2025186248A5 (https=) | 2026-01-20 |
Family
ID=83154407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553498A Active JP7792426B2 (ja) | 2021-03-03 | 2022-03-01 | 極めて強力なｍ－ｃｅｎｋ細胞及び方法 |
| JP2025135655A Pending JP2025186248A (ja) | 2021-03-03 | 2025-08-18 | 極めて強力なｍ－ｃｅｎｋ細胞及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553498A Active JP7792426B2 (ja) | 2021-03-03 | 2022-03-01 | 極めて強力なｍ－ｃｅｎｋ細胞及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240228964A9 (https=) |
| EP (1) | EP4301846A4 (https=) |
| JP (2) | JP7792426B2 (https=) |
| KR (1) | KR20230137392A (https=) |
| AU (2) | AU2022230374B2 (https=) |
| CA (1) | CA3211456A1 (https=) |
| WO (1) | WO2022187207A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024206936A2 (en) * | 2023-03-30 | 2024-10-03 | The Trustees Of The University Of Pennsylvania | Interleukin-18 pretreatment as a cryoprotectant for lymphocytes |
| WO2024205965A1 (en) * | 2023-03-31 | 2024-10-03 | Immunitybio, Inc. | Il-12/il-18 superkines |
| WO2026024752A1 (en) | 2024-07-23 | 2026-01-29 | Immunitybio, Inc. | Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102867975B1 (ko) * | 2017-03-06 | 2025-10-14 | 알토 바이오사이언스 엘엘씨 | Il-12 및 il-18로의 il-15-기반 융합 |
| US20210008107A1 (en) * | 2019-07-08 | 2021-01-14 | Nantkwest, Inc. | CIML NK cells and Methods Therefor |
| AU2019456283B2 (en) | 2019-07-08 | 2023-06-08 | Immunitybio, Inc. | Mononuclear cell derived NK cells |
| WO2021006876A1 (en) * | 2019-07-08 | 2021-01-14 | Nantkwest, Inc. | Ciml nk cells and methods therefor |
-
2022
- 2022-03-01 JP JP2023553498A patent/JP7792426B2/ja active Active
- 2022-03-01 CA CA3211456A patent/CA3211456A1/en active Pending
- 2022-03-01 WO PCT/US2022/018290 patent/WO2022187207A1/en not_active Ceased
- 2022-03-01 EP EP22763876.4A patent/EP4301846A4/en active Pending
- 2022-03-01 US US18/278,797 patent/US20240228964A9/en active Pending
- 2022-03-01 AU AU2022230374A patent/AU2022230374B2/en active Active
- 2022-03-01 KR KR1020237028935A patent/KR20230137392A/ko active Pending
-
2025
- 2025-06-26 AU AU2025204845A patent/AU2025204845A1/en active Pending
- 2025-08-18 JP JP2025135655A patent/JP2025186248A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025186248A5 (https=) | ||
| Zhou et al. | Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-α plays a critical role in maintaining secondary immunity in the absence of IFN-γ | |
| Gorelik et al. | Role of NK cells in the control of metastatic spread and growth of tumor cells in mice | |
| AU665955B2 (en) | Method for improving autologous transplantation | |
| JP2022546486A5 (https=) | ||
| JP3825043B2 (ja) | 対宿主移植片疾患を予防するためのインターロイキン−１２の使用 | |
| JP2001149069A (ja) | ナチュラルキラー細胞の増殖方法 | |
| JP5989727B2 (ja) | 造血におけるｉｌ−１２の使用 | |
| WO2003070921A1 (fr) | PROCÉDÉS DE PRODUCTION DE LYMPHOCYTES ϜδT | |
| Charak et al. | Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy | |
| Amemiya et al. | Liver regeneration is impaired in macrophage colony stimulating factor deficient mice after partial hepatectomy: the role of M-CSF-induced macrophages | |
| Rutten et al. | Local interleukin-2 therapy in bovine ocular squamous cell carcinoma: a pilot study | |
| JP2018522880A (ja) | デングウイルス及び樹状細胞による併用療法のための組成物及び方法 | |
| Jones | The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease | |
| Muramoto et al. | Vascular endothelial cells produce soluble factors that mediate the recovery of human hematopoietic stem cells after radiation injury | |
| JP4371437B2 (ja) | 悪性腫瘍の治療方法 | |
| ES2482141T3 (es) | Terapia con células alogénicas para el tratamiento de una infección oportunista | |
| Pitchenik et al. | Lung natural killer and interleukin-2 activity in lung cancer: A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma | |
| JPH08510131A (ja) | 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用 | |
| Fujii et al. | Recipient-mediated effect of a traditional Chinese herbal medicine, ren-shen-yang-rong-tang (Japanese name: ninjin-youei-to), on hematopoietic recovery following lethal irradiation and syngeneic bone marrow transplantation | |
| Renz et al. | Tumor necrosis factor-α, interleukin 1, eicosanoid, and hydrogen peroxide release from macrophages exposed to glove starch particles | |
| Ageyama et al. | Safe and efficient methods of autologous hematopoietic stem cell transplantation for biomedical research in cynomolgus monkeys | |
| US6213127B1 (en) | Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity | |
| Cotton | Treatment proposed for chronic fatigue syndrome; research continues to compile data on disorder | |
| Scorza et al. | The effect of transfusions on the incidence of bacterial infection |